Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

@article{Thomas2006HypoxiainducibleFD,
  title={Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer},
  author={George V. Thomas and Chris Tran and Ingo K. Mellinghoff and Derek S. Welsbie and Emily W Chan and Barbara J. Fueger and Johannes G Czernin and Charles L. Sawyers},
  journal={Nature Medicine},
  year={2006},
  volume={12},
  pages={122-127}
}
Inhibitors of the kinase mammalian target of rapamycin (mTOR) have shown sporadic activity in cancer trials, leading to confusion about the appropriate clinical setting for their use. Here we show that loss of the Von Hippel-Lindau tumor suppressor gene (VHL) sensitizes kidney cancer cells to the mTOR inhibitor CCI-779 in vitro and in mouse models. Growth arrest caused by CCI-779 correlates with a block in translation of mRNA encoding hypoxia-inducible factor (HIF1A), and is rescued by… Expand
Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
The VHL tumor-suppressor gene is mutated or silenced in most clear cell renal carcinomas (RCCs). pVHL loss results in the stabilization of the heterodimeric transcription factor hypoxia-inducibleExpand
The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer
TLDR
With an increasing number of active agents for treatment of patients with RCC, efforts must continue to develop patient selection models based on predictive biomarkers to direct therapy to appropriate patients. Expand
Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma
TLDR
Encouraging preclinical data warrant clinical trials evaluating [ 18F]FDG and [18F]FLT-PET for monitoring treatment with mTOR inhibitors in patients, and the effects of rapamycin on glucose and thymidine metabolism could be imaged noninvasively by PET. Expand
Mechanism of action of everolimus in renal cell carcinoma
TLDR
Everolimus (RAD001), a synthetic, orally bioavailable analog of rapamycin, is a specific inhibitor of mTOR currently being developed for RCC and other types of cancer. Expand
Treatment of kidney cancer
TLDR
HIF, especially HIF2α, appears to play a causal role in clear cell renal carcinogenesis based on genotype‐phenotype correlations in VHL disease, laboratory experiments with human VHL−/− renal carcinoma cell lines, and genetically engineered mouse models, and Deregulation of HIF almost certainly accounts for the high levels of vascular endothelial growth factor observed in kidney cancer and relates to their sensitivity to VEGF inhibitors. Expand
Translational studies in urologic oncology Clinical implications of hypoxia inducible factor in renal cell carcinoma
TLDR
A directed review of recent discoveries defining the role of HIF in renal tumorigenesis and their relevance to the clinical advances in targeted therapy for advanced RCC is provided. Expand
Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy
  • G. Melillo
  • Medicine, Biology
  • Molecular Cancer Research
  • 2006
TLDR
Identification and validation of pharmacodynamic end points relevant to the HIF-1 pathway is essential for a rational development of HIF inhibitors and integration of these biomarkers in early clinical trials may provide valuable information to determine the contribution of Hif inhibitors to response to therapy. Expand
Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-d-glucose under hypoxia in lung cancer cell lines
TLDR
It is suggested that the intrinsic expression of AKT, mTOR, and HIF in lung cancer, as well as other tumor types, may be important in dictating the decision on how best to use 2-DG alone or in combination with CCI-799 to kill hypoxic tumor cells clinically. Expand
Evaluation of HIF-1 inhibitors as anticancer agents.
  • G. Semenza
  • Biology, Medicine
  • Drug discovery today
  • 2007
TLDR
In animal models, HIF-1 overexpression is associated with increased tumor growth, vascularization, and metastasis, whereas Hif-1 loss-of-function has the opposite effect, thus validating HIF -1 as a target. Expand
Optimal targeting of the mTORC1 kinase in human cancer.
TLDR
This review addresses optimization of clinical development in the context of mTORC1 inhibitor-induced activation of survival pathways, crosstalk between different signaling modules involved in malignant transformation, definition of rational target combination scenarios and biologically based dosing and patient stratification strategies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
TLDR
It is reported that mTOR inhibition induced apoptosis of epithelial cells and the complete reversal of a neoplastic phenotype in the prostate of mice expressing human AKT1 in the ventral prostate, and that clinical resistance to mTOR inhibitors may emerge through BCL2 expression and/or upregulation of HIF-1α activity. Expand
HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression
TLDR
It is demonstrated that HER2 signaling induced by overexpression in mouse 3T3 cells or heregulin stimulation of human MCF-7 breast cancer cells results in increased HIF-1α protein and VEGF mRNA expression that is dependent upon activity of PI3K, AKT, and the downstream kinase FRAP. Expand
Role of VHL gene mutation in human cancer.
  • William Y. Kim, W. Kaelin
  • Biology, Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Preliminary data indicate that HIF plays a critical role in pVHL-defective tumor formation, raising the possibility that drugs directed against HIF or its downstream targets (such as vascular endothelial growth factor) might one day play a role in the treatment of hemangioblastoma and renal cell carcinoma. Expand
Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin
TLDR
These studies position mTOR as an upstream activator of HIF-1 function in cancer cells and suggest that the antitumor activity of rapamycin is mediated, in part, through the inhibition of cellular responses to hypoxic stress. Expand
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.
TLDR
It is shown that tumor suppression by pV HL can be overridden by a HIF variant that escapes pVHL control and established that activation of HIF target genes can promote tumorigenesis in vivo. Expand
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
TLDR
It is demonstrated that in human prostate cancer cells, basal-, growth factor- and mitogen-induced expression of hypoxia-inducible factor 1 (HIF-1) alpha, the regulated subunit of the transcription factor Hif-1, is blocked by LY294002 and rapamycin, inhibitors of PI3K and FRAP, respectively. Expand
HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.
TLDR
It is shown that in the kidneys of patients with VHL disease, HIF activation is an early event occurring in morphologically normal single cells within the renal tubules, while dysplastic lesions, cystic lesions, and tumors showed evidence of additional mechanisms that amplify HIFactivation. Expand
Targeting the molecular target of rapamycin (mTOR)
  • E. Rowinsky
  • Medicine, Biology
  • Current opinion in oncology
  • 2004
TLDR
This review discusses recent findings regarding the principal mechanisms of action of the rapamycins, the potential utility of these agents as anticancer therapeutics, clinical results to date, and developmental challenges that lie ahead. Expand
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.
TLDR
It is demonstrated that competitive inhibition of the VHL substrate recognition site with a peptide derived from the oxygen degradation domain of HIF1alpha recapitulates the tumorigenic phenotype of VHL-deficient tumor cells. Expand
A Novel Hypoxia-inducible Factor-independent Hypoxic Response Regulating Mammalian Target of Rapamycin and Its Targets*
TLDR
Hypoxia rapidly and reversibly triggers hypophosphorylation of mTOR and its effectors 4E-BP1, p70S6K, rpS6, and eukaryotic initiation factor 4G, demonstrating a new mode of regulation of the mTOR pathway and position this pathway as a powerful point of control by O2 of cellular metabolism and energetics. Expand
...
1
2
3
...